Domestic pharmaceutical firm plans NT$1.1 billion investment

ScinoPharm Taiwan Ltd., one of the leading biotechnology companies in the country, said Friday it plans to invest NT$1.1 billion (US$37.6 million) in a project to manufacture high-potency injectable drugs for cancer treatment.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)